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Abstract 
Introduction: adrenal gland, parotid gland, pharynx, eye and bladder are rare localizations of metastases of renal cell carcinoma (RCC). 
We report a case of metachronous RCC metastases to the bladder in a patient with a medical history of transitional cell carcinoma (TCC) 
of the bladder. 
Materials and methods: a case study and review of the relevant literature are presented. 
Results: during a follow-up cystoscopy examination following treatment of TCC, a single 5-mm lesion was detected and endoscopically 
resected. The histology of the resected sample was confirmed to be RCC, comparable to a primary kidney cancer and not recurrent 
TCC. 
Conclusion: the patient had a probability of metastases three years after nephrectomy of 62.9%. Survival rates following single 
metastasectomy are 60% and 38% at three and five years, respectively; metachronous diagnosis has a better prognosis than 
synchronous. During RCC follow-up, each lesion should be considered as a possible metastasis of RCC. 
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Introduction 
The incidence of kidney cancer has grown over the last few 
decades. According to SEER data [1], an estimated 57,760 
individuals (35,430 men and 22,330 women) were diagnosed 
and 12,980 patients died from kidney cancer in 2009 
Among the patients diagnosed with kidney and renal pelvis 
cancer, 58% were diagnosed when the cancer was in a 
localized stage; 18% were diagnosed after the cancer had 
involved regional lymph nodes or progressed directly beyond 
the primary site; 19% were diagnosed after the cancer had 
metastasized and for the remaining 4%, the staging information 
was unknown. The corresponding five-year relative survival 
rates were: 90.4% for localized disease; 62.3% for cancer that 
has progressed to regional lymph nodes involvement; 10.4% for 
distant metastases; and 37.5% for unstaged disease [1]. 
Stage and grade at diagnosis influence the prognosis of kidney 
and renal pelvis cancer; conversely, the outcome of the disease 
does not seem to be related to patient age [2]. 
Renal cell carcinoma (RCC), even if organ confined, can recur 
at any time after nephrectomy. The Mayo Clinic Scoring System 
can be used to predict the percentage survival rate and 
metastases risk on the basis of pathological stage, tumour size, 
regional lymph node status, nuclear grade and the presence of 
necrosis [3].  
The RCC usually metastasizes via the haematogenous and 
lymphatic systems, involving the lung (50–60%),  lymph node 
(40–60%), liver (30–40%), bone (30–40%), brain (5%), bowel 
(4%), pancreas (1%) and rarely the adrenal gland, parotid gland 
and pharynx [4]. A case of RCC ocular metastases has also 
been reported [5]. The bladder is a very unusual site of 
metastases, and in particular no cases have previously been 
described in Italy [6–9]. 
  
Materials and methods 
We describe the case of a 65-year-old patient affected by 
bladder transitional cell carcinoma (TCC), RCC and 
adenocarcinoma of the prostate.  
Bladder TCC was diagnosed elsewhere in 1993; the patient 
underwent trans-urethral resection of bladder tumour (TCC 
stage Tx grade G2). He received no adjuvant therapy and
continued to attend for regular endoscopic follow-up. The 
bladder tumour recurred twice: in 1997 (TCC T1G1) and in 2006 
(TCC T1G2 associated with carcinoma in situ). He was 
administered bacillus Calmette-Guérin for 36 months, following 
the Southwest Oncology Group schedule [10]. 
In 2005, when he presented the for first time at the European 
Institute of Oncology, a cT2N0M0 prostate cancer was 
diagnosed (combined Gleason score 8 [4+4]; prostate specific 
antigen 37.7 ng/ml). An abdominal computed tomography scan 
revealed incidental presence of kidney cancer. Thus, the patient 
underwent a left radical nephrectomy and lymphadenectomy for 
an RCC pT3a pN0, Fuhrman grade III. The tumour was <10 cm 
in diameter and was necrotic. The patient subsequently 
underwent radiation therapy for prostate cancer (66 Gy). No 
evidence of prostate cancer recurrence was found in three 
years of regular follow-up. 
In February 2009, a 5-mm lesion was found during the 
cystoscopy performed as a follow-up for the TCC. This lesion 
was endoscopically resected and histology was that of clear cell 
RCC. The diagnosis of RCC metastases was confirmed by 
comparison with the histology of the resected primary kidney 
cancer. Immunohistochemistry was positive for cytokeratin (ck) 
AE1/AE3, ck 7, ck 20, cluster of differentiation (CD10) and beta 
catenin, and negative for c kit, PSA and FAP (fibroblast 
activation protein). 
 
Discussion 
Renal cell carcinoma rarely metastasizes to the bladder. Kagota 
et al [6] reported 30 cases in Japan; few other cases are 
described in the literature [8,9]. 
Due to the infrequency of this site for RCC metastases, the 
management of these lesions described in the literature varies 
considerably. 
As far as management of single renal cell carcinoma 
metastases is concerned, as reported in 2005 by the 
Tongaonkar group [4], complete resection either by excision or 
radiotherapy is justified and can contribute to long-term survival. 
The first metastasectomy was performed by Barney [11] in 1939 
in a patient with a lung secondary tumour, who died 23 years 
later of coronary artery disease. 
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In fact, the decision to perform metastasectomy is usually made 
according to various prognostic criteria: the site and number of 
metastases [12], the completeness of resection of the primary 
tumour, the performance status and the disease-free interval 
from treatment of the primary tumour to the diagnosis of 
metastatic disease. 
Partial cystectomy [6], endoscopic resection [6,7] and 
endoscopic resection followed by interleukin-2 systemic therapy 
[13] have all been used to treat bladder metastases. 
Complete resection of the RCC single metastases is associated 
with five-year survival rates between 35% and 60%. Mean 
survival time after a single metastasectomy is 45 months [4]. 
The longer the disease-free interval, the longer the survival, and 
synchronous metastases seems to correlate to a worse 
prognosis than metachronous metastases.  
Thus, according to the majority of authors, patients with 
metastatic RCC should be offered metastasectomy if the 
likelihood that complete resection of all sites of disease is high. 
Although more data are required to reach a conclusion and the 
curative impact of metastasectomy can be still considered 
uncertain, surgical intervention can provide effective palliation 
for symptomatic metastatic disease in such sites as bone, brain 
and adrenal gland [14,15]. 
The site of mestases can be related to the survival: patients with 
lung and bone metastases have a better prognosis (median 
survival 62 months) than those with liver and brain metastases 
(median survival 22 months), probably because of differences in 
the feasibility of a radical excision [4]. 
For bladder metastases, the three-year survival rate is 80% in 
the case of single metastases and 20% for patients with more
than one site involved. About 50% of patients with multiple 
metastases have a life expectancy of less than one year 
following diagnosis; no difference was found between 
synchronous and metachronous metastases in terms of overall 
survival. The mean time to diagnosis of urinary bladder 
metastases is 28 months after nephrectomy (range 0 to 131 
months) [16]. 
In our case, the diagnosis of bladder metastases was 
metachronous, 36 months after nephrectomy was performed. 
According to the Mayo Clinic scoring system for renal cancer, 
this patient was at high risk of metastases (62.9% at three 
years). 
 
Conclusion 
During the RCC follow-up, every lesion should be considered a 
possible RCC metastasis even if it is not a common site for 
metastasis. As there is no scientific consensus in the 
management of these lesions, we performed a routine 
metastasectomy. Longer follow-up is needed to confirm the 
adequacy of our approach. 
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